Physician profile
Behnam Daghigh
NPI 1629045729
$98,626.76
in general payments reported to CMS, 2019-2025
42 companies · $2,924 in 2025
The $2,924 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $7,070 · 2021: $7,317 · 2022: $5,941 · 2023: $13K · 2024: $20K · 2025: $2,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $8,394 · Travel and Lodging: $1,677 · Education: $614 · Consulting Fee: $18.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,777.90 |
| Food and Beverage | $8,394.36 |
| Travel and Lodging | $1,676.97 |
| Education | $614.31 |
| Consulting Fee | $18.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $42,664.67 | 2019-2025 | Dupixent |
| Genzyme Corporation | $42,644.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,511.48 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,324.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Pfizer INC. | $1,288.72 | 2019-2025 | |
| Csl Behring | $787.38 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $786.79 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Pharming Healthcare, INC. | $497.87 | 2020-2025 | Ruconest |
| Abbvie INC. | $484.17 | 2022-2024 | Rinvoq |
| Grifols USA, LLC | $456.28 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $452.38 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $418.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $393.10 | 2019-2025 | |
| Amgen INC. | $344.46 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $284.55 | 2019-2025 | Odactra, Ragwitek, Grastek |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behnam Daghigh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.